• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Professional Introduction to Compound with CAS No. 1028336-08-4 and Product Name: 4-(4-Bromophenoxy)-benzylamine

4-(4-Bromophenoxy)-benzylamine, identified by the Chemical Abstracts Service Number (CAS No.) 1028336-08-4, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This molecule, featuring a benzylamine moiety linked to a 4-bromophenoxy group, has garnered attention due to its structural uniqueness and potential biological activities. The presence of both aromatic and brominated phenolic components suggests a high degree of reactivity, making it a valuable intermediate in the synthesis of more complex pharmacophores.

The 4-bromophenoxy group, in particular, introduces a halogenated aromatic ring that is commonly utilized in medicinal chemistry for its ability to enhance binding affinity and metabolic stability. This feature is particularly relevant in the development of small-molecule inhibitors targeting enzyme-catalyzed pathways. The benzylamine component, on the other hand, provides a basic nitrogen atom that can participate in hydrogen bonding interactions, further influencing the compound's pharmacokinetic properties.

Recent advancements in computational chemistry have enabled more precise predictions of molecular interactions, allowing researchers to design derivatives of 4-(4-Bromophenoxy)-benzylamine with enhanced specificity and efficacy. For instance, molecular docking studies have been employed to evaluate its potential as a scaffold for kinase inhibitors, particularly those involved in cancer therapeutics. The bromine atom's electron-withdrawing effect can modulate the electronic properties of the aromatic system, thereby fine-tuning the compound's binding profile to biological targets.

In the context of drug discovery, the synthesis of 4-(4-Bromophenoxy)-benzylamine has been optimized using modern catalytic methods to improve yield and purity. Transition metal-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, have been particularly effective in constructing the desired carbon-carbon bonds between the benzylamine and 4-bromophenoxy units. These methodologies align with green chemistry principles by minimizing waste and reducing reliance on hazardous reagents.

The pharmacological potential of 4-(4-Bromophenoxy)-benzylamine has been explored in several preclinical studies. Its structural motif is reminiscent of known bioactive molecules that exhibit anti-inflammatory, antiviral, and anticancer properties. Notably, derivatives of this compound have shown promise in inhibiting Janus kinases (JAKs), which are implicated in various inflammatory diseases and autoimmune disorders. The ability to modulate JAK activity could lead to novel therapeutic strategies for conditions such as rheumatoid arthritis and psoriasis.

Moreover, the brominated phenolic ring in 4-(4-Bromophenoxy)-benzylamine lends itself to further functionalization through techniques like halogen exchange or metal-catalyzed C-H activation. These strategies allow chemists to introduce additional substituents at strategic positions within the molecule, enhancing its pharmacological properties. For example, incorporation of fluorine atoms can improve metabolic stability while maintaining or even increasing binding affinity to biological targets.

From a regulatory perspective, compounds like 4-(4-Bromophenoxy)-benzylamine must undergo rigorous testing to ensure safety and efficacy before entering clinical trials. Analytical techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are employed to confirm structural integrity and purity. These methods are essential for meeting compliance with international standards set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The role of computational modeling in understanding the behavior of 4-(4-Bromophenoxy)-benzylamine cannot be overstated. Quantum mechanical calculations have provided insights into its electronic structure and reactivity patterns, aiding chemists in designing synthetic routes with higher precision. Additionally, pharmacokinetic modeling helps predict how the compound will be absorbed, distributed, metabolized, and excreted by the body—a critical step in drug development.

In conclusion,4-(4-Bromophenoxy)-benzylamine (CAS No. 1028336-08-4) represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features offer opportunities for developing novel therapeutic agents targeting various diseases. As research continues to advance with new synthetic methodologies and computational tools, this compound is likely to play an increasingly important role in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)